Notice of Effectiveness · EFFECT
Zura Bio Limited
ZURANASDAQEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-11-03
- Effective time (as filed)
- 16:30:00
- Form
- S-3
Registrant 1
- Registrant
- Zura Bio Ltd
- Registrant CIK
- 0001855644
- File number
- 333-299661
Company context
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in TibuSURE, a Phase 2 study in systemic sclerosis (SSc). NEXUS-PMR, a Phase 2 study in polymyalgia rheumatica (PMR), is planned to be initiated by year-end 2026. Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.